Follow The Filings

CTNM Contineum Therapeutics Inc.

Health Care, filed as Contineum Therapeutics Inc. (CL A), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by CTNM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CTNM insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $1.9M sold by 3 insiders under 10b5-1 plans
  1. Carmine N. Stengone CEO
    Planned sale
    $41K 2,500 shares at $16.46 13% of stake
    Traded Sep 8 Filed Sep 8
    ↗
  2. Carmine N. Stengone CEO
    Planned sale
    $40K 2,500 shares at $16.01 13% of stake
    Traded Aug 3 Filed Aug 3
    ↗
  3. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $17K 1,040 shares at $16.00 0.8% of stake
    Traded Jul 8–9 Filed Jul 10
    ↗
  4. Carmine N. Stengone CEO
    Planned sale
    $40K 2,500 shares at $16.00 13% of stake
    Traded Jul 8 Filed Jul 8
    ↗
  5. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $595K 37,179 shares at $15.99 22% of stake
    Traded Jun 30–Jul 1 Filed Jul 2
    ↗
  6. Tim Watkins CMO & Head of Development
    Planned sale
    $174K 10,833 shares at $16.02 55% of stake
    Traded Jun 30 Filed Jul 1
    ↗
  7. Carmine N. Stengone CEO
    Planned sale
    $160K 10,000 shares at $16.01 37% of stake
    Traded Jun 30 Filed Jul 1
    ↗
  8. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $55K 4,170 shares at $13.16 2.9% of stake
    Traded Jun 1 Filed Jun 1
    ↗
  9. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $55K 4,170 shares at $13.12 2.8% of stake
    Traded May 1 Filed May 1
    ↗
  10. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $56K 4,170 shares at $13.43 2.7% of stake
    Traded Apr 6 Filed Apr 6
    ↗
  11. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $63K 4,170 shares at $15.01 2.7% of stake
    Traded Mar 2 Filed Mar 2
    ↗
  12. Tim Watkins CMO & Head of Development
    Planned sale
    $54K 3,611 shares at $15.02 100% of stake
    Traded Mar 2 Filed Mar 2
    ↗
  13. Carmine N. Stengone CEO
    Planned sale
    $114K 7,100 shares at $16.02 32% of stake
    Traded Feb 24–25 Filed Feb 26
    ↗
  14. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $130K 8,124 shares at $16.02 4.9% of stake
    Traded Feb 24–25 Filed Feb 26
    ↗
  15. Daniel S. Lorrain Chief Scientific Officer
    Planned sale
    $1,600 100 shares at $16.00 0.1% of stake
    Traded Feb 19 Filed Feb 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 20 option exercises.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-K Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2024 FY2025
Revenue $0.00 —
Net income -$42.26M -$59.98M

Balance sheet

Metric FY2024 FY2025
Total current assets $206.39M $267.92M
Total non-current assets * $6.46M $8.72M
Total assets $212.85M $276.64M
Total current liabilities $9.97M $9.74M
Total non-current liabilities * $4.81M $5.91M
Total equity $198.07M $260.99M

Cash flow

Metric FY2024 FY2025
Cash from operations -$32.84M -$55.31M
Cash from investing -$69.74M -$3.71M
Cash from financing $109M $112.68M
Net change in cash $6.42M $53.66M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.